NFKB1 and Pain: Additional studies have shown that Duloxetine and other SNRIs inhibit activation of p38 MAPK and NF-κB, which have both been suggested to contribute to neuropathic pain through a pro-inflammatory cascade.38 However, how this mechanism might impact LF-CIPN remains to be studied.